Generic Zytiga: Abiraterone Acetate ANDA Saturation and NADAC Pricing

The landscape of oral oncology therapeutics has undergone a major transformation as first-generation targeted therapies lose patent protection. Among these, abiraterone acetate—originally launched by Janssen Biotech under the brand name Zytiga—has served as a foundational therapy for metastatic prostate cancer. First approved by the FDA in 2011, Zytiga achieved blockbuster commercial status, generating billions of dollars globally. Because metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) require continuous treatment, managing abiraterone acquisition costs is a major priority for commercial payers and government health plans.

The patent cliff for abiraterone acetate led to intense competition in the generic market. Today, the abiraterone market features 15 approved Abbreviated New Drug Applications (ANDAs) held by generic manufacturers. The resulting price erosion has reduced retail pharmacy acquisition costs for the drug close to its marginal cost of production. However, the abiraterone market is not a simple commodity generic space. It is characterized by three distinct New Drug Applications (NDAs) that represent plain abiraterone, an ultramicrosize nanocrystal formulation, and a combination product containing a PARP inhibitor.

This report provides a detailed analysis of the abiraterone acetate market. We examine the Orange Book landscape of approved NDAs and ANDAs, analyze the current acquisition costs using CMS National Average Drug Acquisition Cost (NADAC) data, compare the clinical and formulation differences of the brand-name products, and explore the payer formulary designs that govern access to these therapies.

Short Answer

Yes, generic abiraterone acetate tablets (generic Zytiga) are widely available in the United States. Janssen’s original brand Zytiga (NDA 202379) faces direct competition from 15 approved generic ANDAs held by 13 distinct sponsors, including Amneal, Hikma, Rising, Wockhardt, Dr. Reddy's, Teva, Mylan, Apotex, Glenmark, MSN, Qilu, Florida, and Novugen. The first generic versions entered the market in late 2018 following patent litigation, and the market reached full multi-source saturation in 2020.

According to the FDA Orange Book (as of June 2026), there are 18 unique approved applications for abiraterone acetate: 3 brand NDAs and 15 generic ANDAs. According to CMS NADAC data, the standard abiraterone acetate 250 mg tablet has a pharmacy acquisition cost of $0.90511 per tablet (NDC 00143959721, effective December 17, 2025). A standard therapeutic dose of 1,000 mg daily (taken as four 250 mg tablets once daily) costs approximately $108.61 per month. The 500 mg tablet has a NADAC of $3.75976 per tablet (NDC 00378692191, effective December 17, 2025). Brand-name Zytiga is no longer listed in CMS NADAC, reflecting near-complete generic conversion and the widespread exclusion of the brand from PBM formularies.

Who This Is For

This report is designed for pharmacy directors, oncology formulary managers, biopharmaceutical commercial strategy teams, patent litigation analysts, and oncology pharmacy specialists. It provides data-driven insights into oral oncology generic erosion, formulation life-cycle management, and specialty drug contracting.

For readers interested in how abiraterone fits into the broader oncology landscape, see our analysis on the 2026 to 2032 patent cliff by the numbers. For details on upcoming oral oncology generic launches, see the generic Imbruvica availability timeline.

---

Three Brand NDAs: Formulations and Clinical Differences

To understand the abiraterone acetate market, it is essential to distinguish between the three distinct brand NDAs approved by the FDA. These applications represent three different formulation strategies: plain abiraterone, nanocrystal abiraterone, and a dual-action combination tablet.

+---------------------------------------------------------------------------------+
|                       Abiraterone Acetate Brand Portfolio                       |
+---------------------------------------------------------------------------------+
|                                                                                 |
|  [Zytiga (NDA 202379)]                                                          |
|  - Standard abiraterone acetate (250 mg and 500 mg tablets).                    |
|  - Bioavailability is highly dependent on food (must take on empty stomach).   |
|  - Facing competition from 15 approved generic ANDAs.                           |
|                                                                                 |
|  [Yonsa (NDA 210308)]                                                           |
|  - Ultramicrosize nanocrystal formulation (125 mg tablets).                     |
|  - Enhanced oral bioavailability; can be taken with or without food.            |
|  - 500 mg Yonsa dose is bioequivalent to 1000 mg Zytiga.                        |
|                                                                                 |
|  [Akeega (NDA 216793)]                                                          |
|  - Fixed-dose combination (abiraterone acetate + niraparib).                    |
|  - Combined androgen inhibitor and PARP inhibitor.                              |
|  - Indicated specifically for BRCA-mutated mCRPC.                               |
|                                                                                 |
+---------------------------------------------------------------------------------+

1. Zytiga (NDA 202379) - Standard abiraterone acetate

Approved on April 28, 2011, Janssen’s Zytiga is the original standard formulation. It is indicated for use in combination with prednisone for patients with mCRPC and mCSPC.

• The Food Effect: Standard abiraterone acetate is highly lipophilic, and its oral bioavailability increases dramatically when taken with food. Ingestion of abiraterone with a high-fat meal can increase systemic exposure (AUC) by up to 10-fold compared to fasting conditions.
• Clinical and Dosing Risks: Because this food effect is highly variable, administering standard abiraterone with food could lead to unpredictable, potentially toxic drug levels. Therefore, the FDA-approved label mandates that standard abiraterone tablets must be taken on an empty stomach (at least one hour before or two hours after a meal).
• Dosing Regimen: The standard dose is 1,000 mg once daily (administered as either four 250 mg tablets or two 500 mg tablets), paired with prednisone 5 mg twice daily.

2. Yonsa (NDA 210308) - Ultramicrosize (Nanocrystal) abiraterone acetate

Approved on May 22, 2018, and marketed by Sun Pharmaceutical, Yonsa represents a formulation improvement. It utilizes a proprietary SoluMatrix Fine Particle Technology to create ultramicrosize, nanocrystal abiraterone acetate particles.

• Improved Bioavailability: The reduction in particle size increases the surface area of the drug, significantly enhancing its dissolution rate and absorption in the gastrointestinal tract.
• Mitigation of the Food Effect: Because Yonsa is much more efficiently absorbed in the fasted state, its absorption is less dependent on food intake. As a result, Yonsa is approved to be taken with or without food.
• Dose Equivalence: The improved bioavailability allows for a lower total daily dose. A 500 mg daily dose of Yonsa (administered as four 125 mg tablets) achieves equivalent systemic exposure to a 1,000 mg daily dose of Zytiga. Yonsa is administered in combination with methylprednisolone 4 mg twice daily.

3. Akeega (NDA 216793) - Dual-Action Fixed-Dose Combination

Approved on August 11, 2023, Janssen's Akeega is a fixed-dose combination tablet containing abiraterone acetate and niraparib (a PARP inhibitor).

• Targeted Indication: Akeega is indicated specifically for the treatment of adult patients with BRCA-mutated mCRPC. This mutation affects the homologous recombination repair (HRR) pathway, making tumor cells highly vulnerable to PARP inhibition.
• Dual Mechanism of Action: Akeega combines androgen receptor pathway inhibition (via abiraterone) with DNA damage repair inhibition (via niraparib). This dual mechanism helps overcome resistance in BRCA-mutated tumors.
• Clinical Advantage: Delivering both agents in a single fixed-dose combination tablet simplifies the oncology dosing regimen and ensures patients receive optimal concurrent exposure to both mechanisms.

---

FDA Orange Book Landscape: Mapping the 15 Abiraterone ANDAs

The invalidation of Janssen's dosing and formulation patents cleared the way for generic entry. Generic manufacturers filed Abbreviated New Drug Applications (ANDAs) containing Paragraph IV certifications against Janssen's patents, leading to multiple approvals.

An analysis of the FDA Orange Book (as of June 2026) shows 18 unique approved applications for abiraterone acetate products: 3 brand NDAs and 15 approved generic ANDAs. These 15 ANDAs are held by 13 distinct sponsors.

Source: FDA Orange Book, June 2026 snapshot. All 15 ANDA applications hold active therapeutic equivalence ratings (AB) relative to the reference listed drug Zytiga (NDA 202379), enabling generic substitution.

The Chronology of Generic Saturation

The timeline of approvals reveals how the market transitioned from brand exclusivity to multi-source competition:

1. The First Wave (October 2018): On October 31, 2018, the FDA approved the first wave of four generic ANDAs: Hikma, Apotex, Mylan, and Teva. Because multiple sponsors shared first-to-file status, they launched concurrently, initiating immediate price competition.
2. The 2019 Expansion: Throughout 2019, additional major generic sponsors entered the market, including Amneal, Rising, Wockhardt, MSN, Qilu, and Glenmark. This expanded the available supply and drove further price erosion.
3. The 500 mg Approval Wave (2020–2024): While the initial generic launches focused on the 250 mg strength, generic manufacturers subsequently secured approvals for the 500 mg strength (which reduces patient pill burden). Mylan and Amneal secured 500 mg approvals in December 2020, followed by Glenmark (2022), Teva (2023), Dr. Reddy's (2023), and MSN (2024).
4. Specialty Entrants: Subsequent approvals for newer sponsors, such as Novugen (2022) and Florida (2023), further saturated the market, resulting in the current landscape of 15 active ANDAs.

---

Price Analysis: Evaluating Generic Abiraterone NADAC Costs

The National Average Drug Acquisition Cost (NADAC) is a key index for understanding the financial impact of generic competition. Because retail pharmacies purchase both 250 mg and 500 mg strengths of generic abiraterone acetate from wholesalers, NADAC allows payers to evaluate the actual cost-of-treatment dynamics.

Current NADAC Acquisition Prices

Using the CMS NADAC dataset (as of June 2026), we analyze the acquisition costs for generic abiraterone acetate:

• Generic Abiraterone Acetate 250 mg Tablet: The NADAC is $0.90511 per tablet (NDC 00143959721, effective December 17, 2025).
  • The standard daily dose is 1,000 mg, which requires taking four 250 mg tablets once daily.
  • This equates to 120 tablets for a 30-day supply.
  • The total monthly acquisition cost is: $$\text{Monthly Cost} = 120 \times $0.90511 = $108.6132 \approx $108.61$$
• Generic Abiraterone Acetate 500 mg Tablet: The NADAC is $3.75976 per tablet (NDC 00378692191, effective December 17, 2025).
  • The standard daily dose requires taking two 500 mg tablets once daily.
  • This equates to 60 tablets for a 30-day supply.
  • The total monthly acquisition cost is: $$\text{Monthly Cost} = 60 \times $3.75976 = $225.5856 \approx $225.59$$

The Strength-Pricing Anomaly

A notable anomaly in abiraterone pricing is that the 500 mg tablet is significantly more expensive per milligram than the 250 mg tablet:

• At $0.90511 per 250 mg tablet, the cost is $0.00362 per milligram.
• At $3.75976 per 500 mg tablet, the cost is $0.00752 per milligram (more than double the per-milligram cost).
• For a patient on a 1,000 mg daily dose, using 500 mg tablets ($225.59/month) costs $116.98 more per month than using 250 mg tablets ($108.61/month).

This pricing difference occurs because more generic manufacturers supply the 250 mg tablet (12 approved sponsors) than the 500 mg tablet (9 approved sponsors). For payers, this anomaly has led to specific clinical policies: many health plans mandate the use of four 250 mg tablets daily rather than two 500 mg tablets daily to capture the additional savings, unless the patient has a documented clinical need to reduce pill burden.

+---------------------------------------------------------------------------------+
|                    Abiraterone Acetate Monthly Cost Comparison                  |
|                                                                                 |
|  Monthly Cost (1000 mg/day maintenance supply)                                  |
|  [Brand Zytiga]*      ========================================> ~$10,000.00     |
|  [Generic 500 mg]     ====> $225.59                                             |
|  [Generic 250 mg]     => $108.61  (>98.9% Price Erosion)                        |
|                                                                                 |
|  *Note: Brand Zytiga has no active retail NADAC line due to near-100%           |
|  generic conversion. The brand's historical AWP exceeded $10,000 per month.     |
+---------------------------------------------------------------------------------+

Complete Brand Exclusion

Similar to the Tecfidera market, brand-name Zytiga is entirely absent from the CMS NADAC dataset. This reflects a highly efficient generic transition. Because abiraterone is an oral solid tablet, generic substitution occurs automatically at retail and specialty pharmacies. Payers have implemented strict formulary exclusions, directing virtually 100% of the patient volume to the low-cost generic versions.

---

Clinical Safety Monitoring and Drug-Drug Interactions

Despite the low cost of generic abiraterone acetate (priced under $110 per month using 250 mg tablets), it remains a potent oncology medication. It requires careful clinical management and strict safety monitoring. Specialty pharmacies and oncology clinical teams must enforce monitoring protocols to manage the risks associated with CYP17 inhibition.

+---------------------------------------------------------------------------------+
|                       Abiraterone Clinical Monitoring Plan                      |
|                                                                                 |
|  [ ] Liver Function Tests (LFTs)                                                |
|      - Monitor AST, ALT, and bilirubin.                                         |
|      - Frequency: Every 2 weeks for the first 3 months, then monthly.           |
|                                                                                 |
|  [ ] Mineralocorticoid Excess Monitoring                                        |
|      - Monitor blood pressure, serum potassium, and fluid retention.            |
|      - Frequency: Monthly.                                                      |
|                                                                                 |
|  [ ] Cardiovascular & Cardiac Event Screening                                   |
|      - Screen for history of cardiovascular disease, heart failure, or QT       |
|        prolongation. Monitor LVEF if clinically indicated.                      |
|                                                                                 |
|  [ ] Prednisone / Corticosteroid Adherence                                       |
|      - Confirm daily adherence to prednisone (5 mg BID for mCRPC/mCSPC)         |
|        or methylprednisone (4 mg BID for Yonsa) to prevent adrenal crisis.       |
+---------------------------------------------------------------------------------+

1. Hepatotoxicity and LFT Monitoring

Abiraterone acetate can cause severe hepatotoxicity, characterized by transaminase elevations (AST and ALT) and bilirubin elevations. In clinical trials, drug-induced hepatotoxicity led to treatment interruption or discontinuation in approximately 2% to 4% of patients.

• Monitoring Schedule: The FDA-approved label mandates monitoring of serum transaminases (ALT and AST) and bilirubin every two weeks for the first three months of treatment, and monthly thereafter.
• Dose Modification Thresholds: If ALT or AST elevations exceed 5 times the upper limit of normal (ULN), abiraterone dosing must be suspended immediately. Treatment may be restarted at a reduced dose (e.g., 500 mg/day instead of 1,000 mg/day) only after LFTs return to the patient's baseline or below 2.5 times ULN. If LFT elevations recur at the reduced dose, abiraterone must be permanently discontinued.

2. Mineralocorticoid Excess and Corticosteroid Co-administration

Abiraterone inhibits the CYP17 enzyme, which blockades the synthesis of cortisol. This loss of cortisol feedback leads to an increase in adrenocorticotropic hormone (ACTH) secretion, which stimulates the adrenal gland to overproduce mineralocorticoids (specifically deoxycorticosterone).

• Clinical Consequences: Mineralocorticoid excess can lead to severe hypertension, hypokalemia (low potassium), and fluid retention.
• The Mitigating Strategy: To prevent mineralocorticoid excess, abiraterone acetate must be co-administered with a corticosteroid.
  • For standard abiraterone (Zytiga and its generics), patients must take prednisone 5 mg twice daily (for mCRPC) or prednisone 5 mg once daily (for mCSPC).
  • For ultramicrosize abiraterone (Yonsa), patients must take methylprednisolone 4 mg twice daily.
• Safety Monitoring: Patients' blood pressure, serum potassium levels, and signs of fluid retention (such as peripheral edema) must be monitored at least monthly during therapy.

3. Food Administration Protocol and Low-Dose Adaptive Dosing

For patients taking standard generic abiraterone acetate, adherence to the fasting state is a critical safety parameter.

• The Risk: Taking standard abiraterone with a meal can cause unpredictable, highly elevated drug levels, which increases the risk of hepatotoxicity and mineralocorticoid excess.
• Clinical Education: Specialty pharmacies must educate patients to take their tablets on an empty stomach: either at least one hour before eating or two hours after eating. Patients should not eat for at least one hour after taking their dose.
• The Low-Dose Off-Label Alternative: Due to the extreme food effect, clinical trials (including a notable study published in the Journal of Clinical Oncology) have investigated taking a low dose of abiraterone (250 mg) with a low-fat breakfast as an alternative to the standard 1,000 mg fasted dose. This "adaptive dosing" has been shown to achieve comparable systemic drug levels and clinical outcomes (prostate-specific antigen response rates and progression-free survival) while reducing the physical pill burden and financial toxicity for patients without insurance. However, because this practice is off-label and requires strict adherence to a standardized low-fat meal, it is not widely written into commercial payer protocols, and standard labeling continues to mandate the fasted 1,000 mg dose.
• Formulation Switch: For patients who struggle to maintain a fasting schedule, clinicians may consider transitioning the patient to Sun Pharma’s Yonsa (125 mg tablets), which is approved to be taken with or without food.

---

Payer Management: Formulary Positioning and Prior Authorization Criteria

The transition of abiraterone acetate to a highly commoditized generic has shifted the payer focus from managing drug acquisition costs to structuring formulary rules that direct patient volume to the most cost-effective strength (250 mg) and clinical pathway.

1. PBM Formulary Tiering

Virtually all major PBMs (CVS Caremark, Express Scripts, OptumRx) have placed brand-name Zytiga on their formulary exclusion lists. In its place, generic abiraterone acetate 250 mg is positioned as a Preferred Generic (typically Tier 1 or Tier 2).

• Specialty Classification: Although generic abiraterone is a low-cost drug (costing about $108.61 per month at NADAC), PBMs continue to classify it as a specialty medication. This classification means dispensing is routed through preferred specialty pharmacies (such as CVS Specialty, Accredo, or Optum Specialty) rather than local retail pharmacies, allowing plans to maintain clinical management and oversight.
• The 500 mg Copay Penalty: To encourage the use of the cheaper 250 mg strength, some plans place generic abiraterone 500 mg on a higher tier (Tier 3 or non-preferred) or require a separate prior authorization detailing why the patient cannot take four 250 mg tablets once daily.

2. Step Therapy and Clinical Pathways

Before a payer will approve coverage for newer, more expensive branded oral androgen receptor inhibitors (ARIs) such as Pfizer/Astellas's Xtandi (enzalutamide), Janssen's Erleada (apalutamide), or Bayer's Nubeqa (darolutamide), they frequently enforce Step Therapy rules.

• Generic First-Line: Plans mandate that patients with mCRPC or mCSPC must first fail or show clinical intolerance to generic abiraterone acetate before they can receive coverage for Xtandi, Erleada, or Nubeqa.
• Payer Savings Impact: Given that branded ARIs cost between $12,000 and $15,000 per month, enforcing a step through $108-a-month generic abiraterone represents a massive cost-saving lever for commercial plans.

3. Prior Authorization (PA) Clinical Checklist

Specialty pharmacies and oncology clinics must submit detailed clinical evidence to satisfy payer PA criteria. A typical abiraterone PA checklist includes:

• Diagnosis Verification: Documentation of metastatic castration-resistant prostate cancer (mCRPC) or metastatic castration-sensitive prostate cancer (mCSPC).
• Androgen Deprivation Therapy (ADT) Adherence: Confirmation that the patient is receiving concurrent ADT with a gonadotropin-releasing hormone (GnRH) analog (e.g., leuprolide, degarelix) or has a history of bilateral orchiectomy. The patient's serum testosterone must be documented as castrate (typically $<50$ ng/dL) prior to starting therapy.
• Prednisone Combination: Verification that the patient will take abiraterone in combination with prednisone (5 mg twice daily or 5 mg once daily, depending on the indication).
• Hepatic and Cardiovascular Clearance: Confirmation of baseline AST, ALT, and bilirubin levels within acceptable limits (typically $<2.5$ times ULN, or $<5$ times ULN in the presence of liver metastases), and no history of severe NYHA Class III or IV heart failure.

4. Co-pay Assistance and Patient Support

With the brand-name product excluded, patients can no longer use Janssen's Zytiga co-pay savings cards. This change has different implications depending on patient insurance:

• Commercial Insurance: Generic manufacturer co-pay programs are less common and less generous than brand-name programs. However, because the total cost of the drug is low ($108/month at NADAC), patient cost-sharing (typically a flat copay of $10 to $30 for a preferred generic) is manageable for most commercially insured patients.
• Medicare Part D: Under the Medicare Part D redesign, the $2,000 out-of-pocket cap significantly reduces the financial burden on seniors. Generic abiraterone’s low cost helps patients avoid reaching the coverage gap or cap quickly, preserving their benefit for other specialty therapies.

---

FAQ

Are generic abiraterone acetate tablets AB-rated and substitutable for brand Zytiga?

Yes. All 15 approved generic ANDAs for abiraterone acetate listed in the Orange Book hold an AB rating relative to Janssen's brand Zytiga (NDA 202379). This rating confirms that the generic tablets have demonstrated bioequivalence to the brand in clinical testing. Under state pharmacy laws, pharmacists can automatically substitute the generic version for a Zytiga prescription unless the prescriber specifies "no substitution" or "dispense as written."

How does Yonsa (nanocrystal abiraterone) differ from generic abiraterone acetate in regulatory terms?

Yonsa was approved under a separate brand NDA (NDA 210308) rather than an Abbreviated New Drug Application. Because it utilizes a proprietary SoluMatrix nanocrystal formulation that enhances absorption, it is not therapeutic-equivalent (AB-rated) to standard abiraterone acetate (Zytiga or its generics). Pharmacists cannot automatically substitute generic abiraterone for Yonsa. Yonsa is dosed at 500 mg daily (with or without food) in combination with methylprednisolone, whereas standard abiraterone is dosed at 1,000 mg daily (on an empty stomach) in combination with prednisone.

Why is there a significant price difference between the 250 mg and 500 mg generic tablets?

The price difference is driven by market competition. The 250 mg tablet has 12 approved generic sponsors, resulting in aggressive price competition that has driven the NADAC down to $0.90511 per tablet ($108.61 per month). In contrast, the 500 mg tablet has only 9 approved generic sponsors, resulting in less intense price competition and a higher NADAC of $3.75976 per tablet ($225.59 per month).

---

Sources

• U.S. Food and Drug Administration, Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Search criteria: "Abiraterone Acetate" (NDAs 202379, 210308, 216793; ANDAs 208339, 208453, 208446, 208432, 208327, 208371, 208380, 210686, 212462, 208416, 215947, 209227, 212206, 210726, 215086). https://www.accessdata.fda.gov/scripts/cder/ob/
• Centers for Medicare & Medicaid Services (CMS), National Average Drug Acquisition Cost (NADAC) Files, June 10, 2026 snapshot (most recent effective date December 17, 2025). NDCs compared: Generic Abiraterone Acetate 250 mg (00143-9597-21) and 500 mg (00378-6921-91). https://www.medicaid.gov/medicaid/prescription-drugs/pharmacy-pricing/index.html
• U.S. Food and Drug Administration, Drugs@FDA Database. Product labels for Zytiga (NDA 202379), Yonsa (NDA 210308), and Akeega (NDA 216793). https://www.accessdata.fda.gov/scripts/cder/daf/
• U.S. Food and Drug Administration, FDA Enforcement Reports and Recalls Database. Product safety query: "Abiraterone Acetate" (returning zero recall events). https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts

---

Disclaimer: This article provides independent regulatory, clinical-pipeline, and market-access analysis for biopharma professionals and does not constitute clinical, legal, or investment advice.